Before its recent Phase 3 LSD win, Definium modeled up to $70,000 a year for a therapy that could fill a clinical shift

New York City–based Definium recently announced positive data from its Phase 3 Voyage trial of DT120, an orally disintegrating 100 µg dose of LSD in adults with generalized anxiety disorder (GAD). The company announced positive Phase 3 results for the same compound for major depressive disorder (MDD) in June. Now the company needs to convince… The post Before its recent Phase 3 LSD win, Definium…